- $8.72bn
- $8.22bn
- $108.78m
- 34
- 12
- 95
- 44
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 83.06 | ||
| PEG Ratio (f) | 1.04 | ||
| EPS Growth (f) | 394.74% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 15.53 | ||
| Price to Tang. Book | 15.53 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 30.33 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -11.66% | ||
| Return on Equity | -19.88% | ||
| Operating Margin | -27.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 53.45 | 82.27 | 132.3 | 69.86 | 108.78 | 376.65 | 547.1 | -1.18% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +394.74 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ImmunoGen, Inc. is a commercial-stage biotechnology company. The Company is focused on developing and commercializing of antibody- drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its ELAHERE (Mirvetuximab Soravtansine) is a first-in-class ADC targeting folate receptor alpha (FRa), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Its Pivekimab sunirine (PVEK), is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. The Company is advancing PVEK in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).
Directors
- Stephen Mccluski NEC (69)
- Mark Enyedy PRE (57)
- Susan Altschuller CFO (39)
- Anna Berkenblit SVP (51)
- Stacy Coen SVP (50)
- Kristen Harrington-smith SVP
- Mimi Huizinga SVP
- Thomas Ryll SVP (60)
- Theresa Wingrove SVP (63)
- Tracey Mccain DRC
- Stuart Arbuckle IND (55)
- Mark Goldberg IND (66)
- Dean Mitchell IND (65)
- Kristine Peterson IND (62)
- Helen Thackray IND (52)
- Richard Wallace IND (69)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- March 27th, 1981
- Public Since
- November 17th, 1989
- No. of Shareholders
- 398
- No. of Employees
- 277
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 279,354,016
- Address
- 830 Winter Street, WALTHAM, 02451
- Web
- https://www.immunogen.com/
- Phone
- +1 7818950600
- Auditors
- Ernst & Young LLP
Upcoming Events for IMGN
Q1 2024 ImmunoGen Inc Earnings Release
Immunogen Inc Annual Shareholders Meeting
Q2 2024 ImmunoGen Inc Earnings Release
Similar to IMGN
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the ImmunoGen share price?
As of Today at 18:11 UTC, shares in ImmunoGen are trading at $31.23. This share price information is delayed by 15 minutes.
How has the ImmunoGen share price performed this year?
Shares in ImmunoGen last closed at $31.23 and the price had moved by +641.81% over the past 365 days. In terms of relative price strength the ImmunoGen share price has outperformed the S&P500 Index by +503.65% over the past year.
What are the analyst and broker recommendations for ImmunoGen?
The overall consensus recommendation for ImmunoGen is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the ImmunoGen dividend yield?
ImmunoGen does not currently pay a dividend.
Does ImmunoGen pay a dividend?
ImmunoGen does not currently pay a dividend.
When does ImmunoGen next pay dividends?
ImmunoGen does not currently pay a dividend.
How do I buy ImmunoGen shares?
To buy shares in ImmunoGen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ImmunoGen?
As of the previous close price of $31.23, shares in ImmunoGen had a market capitalisation of $8.72bn.
Where are ImmunoGen shares listed?
Here are the trading details for ImmunoGen:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: IMGN
What kind of share is ImmunoGen?
Based on an overall assessment of its quality, value and momentum ImmunoGen is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ImmunoGen share price forecast for 2024?
The analyst consensus target price for shares in ImmunoGen is $31.06. That is 0.54% below the last closing price of $31.23.
Analysts covering ImmunoGen currently have a consensus Earnings Per Share (EPS) forecast of $0.08 for the next financial year.
Find out moreWhat is the trend in the ImmunoGen share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ImmunoGen. Over the past six months, its share price has outperformed the S&P500 Index by +94.12%.
As of the last closing price of $31.23, shares in ImmunoGen were trading +64.36% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ImmunoGen PE Ratio?
The ImmunoGen PE ratio based on its reported earnings over the past 12 months is 83.06. The shares last closed at $31.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ImmunoGen?
ImmunoGen's management team is headed by:
- Stephen Mccluski - NEC
- Mark Enyedy - PRE
- Susan Altschuller - CFO
- Anna Berkenblit - SVP
- Stacy Coen - SVP
- Kristen Harrington-smith - SVP
- Mimi Huizinga - SVP
- Thomas Ryll - SVP
- Theresa Wingrove - SVP
- Tracey Mccain - DRC
- Stuart Arbuckle - IND
- Mark Goldberg - IND
- Dean Mitchell - IND
- Kristine Peterson - IND
- Helen Thackray - IND
- Richard Wallace - IND